Possible Insufficiency of Generic Price Competition to Contain Prices for Orally Administered Anticancer Therapies.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 28892541.
- Also identified by DOI 10.1001/jamainternmed.2017.2788 and PMC identifier 5820701.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This study traces the use of the anticancer drug capecitabine through its loss of patent protection to evaluate the effect of generic pricing on the cost of oral anticancer drugs.
Medical subject headings
- Antineoplastic Agents
- Capecitabine
- Drug Costs
- Drugs, Generic